Literature DB >> 29308799

An enzymatic advance in nicotine cessation therapy.

Song Xue1, Marsida Kallupi, Bin Zhou, Lauren C Smith, Pedro O Miranda, Olivier George, Kim D Janda.   

Abstract

A nicotine-degrading enzyme termed NicA2 was altered (NicA2-J1) through fusion of an albumin binding domain to increase its half-life. Examination of NicA2-J1 in vivo demonstrated a complete blockade of brain nicotine access, which in turn blunted nicotine's psychoactive effects. These data further support development of pharmacokinetic nicotine cessation therapeutics.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29308799      PMCID： PMC6231713          DOI： 10.1039/c7cc09134f

Source DB:  PubMed          Journal:  Chem Commun (Camb)        ISSN： 1359-7345            Impact factor:   6.222


  27 in total

1.  Effects of repeated withdrawal episodes, nicotine dose, and duration of nicotine exposure on the severity and duration of nicotine withdrawal in rats.

Authors:  Karen L Skjei; Athina Markou
Journal:  Psychopharmacology (Berl)       Date:  2003-04-24       Impact factor: 4.530

2.  Engineering of a femtomolar affinity binding protein to human serum albumin.

Authors:  Andreas Jonsson; Jakob Dogan; Nina Herne; Lars Abrahmsén; Per-Ake Nygren
Journal:  Protein Eng Des Sel       Date:  2008-05-22       Impact factor: 1.650

3.  Paw withdrawal threshold in the von Frey hair test is influenced by the surface on which the rat stands.

Authors:  G M Pitcher; J Ritchie; J L Henry
Journal:  J Neurosci Methods       Date:  1999-03-01       Impact factor: 2.390

4.  Reward and somatic changes during precipitated nicotine withdrawal in rats: centrally and peripherally mediated effects.

Authors:  S S Watkins; L Stinus; G F Koob; A Markou
Journal:  J Pharmacol Exp Ther       Date:  2000-03       Impact factor: 4.030

5.  Efficacy of the nicotine vaccine 3'-AmNic-rEPA (NicVAX) co-administered with varenicline and counselling for smoking cessation: a randomized placebo-controlled trial.

Authors:  Philippe H J Hoogsteder; Daniel Kotz; Paul I van Spiegel; Wolfgang Viechtbauer; Onno C P van Schayck
Journal:  Addiction       Date:  2014-06-03       Impact factor: 6.526

Review 6.  Update on medicines for smoking cessation.

Authors:  Mike McDonough
Journal:  Aust Prescr       Date:  2015-08-03

7.  Rodent model of nicotine abstinence syndrome.

Authors:  D H Malin; J R Lake; P Newlin-Maultsby; L K Roberts; J G Lanier; V A Carter; J S Cunningham; O B Wilson
Journal:  Pharmacol Biochem Behav       Date:  1992-11       Impact factor: 3.533

8.  Systematic unraveling of the unsolved pathway of nicotine degradation in Pseudomonas.

Authors:  Hongzhi Tang; Lijuan Wang; Weiwei Wang; Hao Yu; Kunzhi Zhang; Yuxiang Yao; Ping Xu
Journal:  PLoS Genet       Date:  2013-10-24       Impact factor: 5.917

9.  VTA CRF neurons mediate the aversive effects of nicotine withdrawal and promote intake escalation.

Authors:  Taryn E Grieder; Melissa A Herman; Candice Contet; Laura A Tan; Hector Vargas-Perez; Ami Cohen; Michal Chwalek; Geith Maal-Bared; John Freiling; Joel E Schlosburg; Laura Clarke; Elena Crawford; Pascale Koebel; Vez Repunte-Canonigo; Pietro P Sanna; Andrew R Tapper; Marisa Roberto; Brigitte L Kieffer; Paul E Sawchenko; George F Koob; Derek van der Kooy; Olivier George
Journal:  Nat Neurosci       Date:  2014-11-17       Impact factor: 24.884

10.  Animal models of nicotine exposure: relevance to second-hand smoking, electronic cigarette use, and compulsive smoking.

Authors:  Ami Cohen; Olivier George
Journal:  Front Psychiatry       Date:  2013-06-04       Impact factor: 4.157
View more
  8 in total

1.  Exposure to passive nicotine vapor in male adolescent rats produces a withdrawal-like state and facilitates nicotine self-administration during adulthood.

Authors:  Marsida Kallupi; Giordano de Guglielmo; Estefania Larrosa; Olivier George
Journal:  Eur Neuropsychopharmacol       Date:  2019-08-26       Impact factor: 4.600

2.  Chronic voluntary caffeine intake in male Wistar rats reveals individual differences in addiction-like behavior.

Authors:  Christine H Lee; Olivier George; Adam Kimbrough
Journal:  Pharmacol Biochem Behav       Date:  2020-02-24       Impact factor: 3.533

3.  Crystallography Coupled with Kinetic Analysis Provides Mechanistic Underpinnings of a Nicotine-Degrading Enzyme.

Authors:  Margarita A Tararina; Song Xue; Lauren C Smith; Samantha N Muellers; Pedro O Miranda; Kim D Janda; Karen N Allen
Journal:  Biochemistry       Date:  2018-06-13       Impact factor: 3.162

Review 4.  Advances in smoking cessation pharmacotherapy: Non-nicotinic approaches in animal models.

Authors:  Lauren C Smith; Olivier George
Journal:  Neuropharmacology       Date:  2020-08-03       Impact factor: 5.250

5.  Oxycodone self-administration and withdrawal behaviors in male and female Wistar rats.

Authors:  Adam Kimbrough; Jenni Kononoff; Sierra Simpson; Marsida Kallupi; Sharona Sedighim; Kenia Palomino; Dana Conlisk; Jeremiah D Momper; Giordano de Guglielmo; Olivier George
Journal:  Psychopharmacology (Berl)       Date:  2020-02-29       Impact factor: 4.530

6.  An enzymatic approach reverses nicotine dependence, decreases compulsive-like intake, and prevents relapse.

Authors:  Marsida Kallupi; Song Xue; Bin Zhou; Kim D Janda; Olivier George
Journal:  Sci Adv       Date:  2018-10-17       Impact factor: 14.136

7.  Adolescent cannabinoid exposure induces irritability-like behavior and cocaine cross-sensitization without affecting the escalation of cocaine self-administration in adulthood.

Authors:  Jenni Kononoff; Philippe A Melas; Marsida Kallupi; Giordano de Guglielmo; Adam Kimbrough; Maria Scherma; Paola Fadda; Denise B Kandel; Eric R Kandel; Olivier George
Journal:  Sci Rep       Date:  2018-09-17       Impact factor: 4.379

8.  The nicotine-degrading enzyme NicA2 reduces nicotine levels in blood, nicotine distribution to brain, and nicotine discrimination and reinforcement in rats.

Authors:  Paul R Pentel; Michael D Raleigh; Mark G LeSage; Thomas Thisted; Stephen Horrigan; Zuzana Biesova; Matthew W Kalnik
Journal:  BMC Biotechnol       Date:  2018-07-24       Impact factor: 2.563
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.